These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35572740)

  • 1. Virucidal Effect of Povidone Iodine on SARS-CoV-2 in Nasopharynx: An Open-label Randomized Clinical Trial.
    Kamal Arefin M; Banu SS; Nasir Uddin AKM; Nurul Fattah Rumi SK; Khan M; Kaiser A; Arafat MS; Chowdhury JA; Khan MAS; Hasan MJ
    Indian J Otolaryngol Head Neck Surg; 2022 Oct; 74(Suppl 2):3283-3292. PubMed ID: 35572740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial.
    Hasan MJ; Rumi SKNF; Banu SS; Uddin AKMN; Islam MS; Arefin MK
    Trials; 2021 Jan; 22(1):2. PubMed ID: 33397432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial.
    Arefin MK; Rumi SKNF; Uddin AKMN; Banu SS; Khan M; Kaiser A; Chowdhury JA; Khan MAS; Hasan MJ
    Indian J Otolaryngol Head Neck Surg; 2022 Oct; 74(Suppl 2):2963-2967. PubMed ID: 34026595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.
    Zarabanda D; Vukkadala N; Phillips KM; Qian ZJ; Mfuh KO; Hatter MJ; Lee IT; Rao VK; Hwang PH; Domb G; Patel ZM; Pinsky BA; Nayak JV
    Laryngoscope; 2022 Nov; 132(11):2089-2095. PubMed ID: 34724213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pilot Study of 0.4% Povidone-Iodine Nasal Spray to Eradicate SARS-CoV-2 in the Nasopharynx.
    Sirijatuphat R; Leelarasamee A; Puangpet T; Thitithanyanont A
    Infect Drug Resist; 2022; 15():7529-7536. PubMed ID: 36575672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID-19.
    Batioglu-Karaaltin A; Yigit O; Cakan D; Akgul O; Yigit E; Yilmaz YZ; Cakir KB; Ciftci G; Boyoğlu NS; Cagliyan A; Can E; Dikme O; Hacioglu Y; Balkan II; Enver O; Ozdogan HA
    Clin Otolaryngol; 2023 Jul; 48(4):623-629. PubMed ID: 36973223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in reverse transcription polymerase chain reaction cycle threshold values of SARS-CoV-2 with topical povidone iodine use: A single-arm open-label interventional study.
    Shankar S; Jamir L; Kakkar R; Babji K; Mangayarkarasi V; Tripathi M; Tak H
    J Family Med Prim Care; 2022 Feb; 11(2):480-486. PubMed ID: 35360801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2.
    Frank S; Brown SM; Capriotti JA; Westover JB; Pelletier JS; Tessema B
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1054-1058. PubMed ID: 32940656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2).
    Pelletier JS; Tessema B; Frank S; Westover JB; Brown SM; Capriotti JA
    Ear Nose Throat J; 2021 Apr; 100(2_suppl):192S-196S. PubMed ID: 32951446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of povidone-iodine nasal rinse and mouth wash in COVID-19 management: a prospective, randomized pilot clinical trial (povidone-iodine in COVID-19 management).
    Alsaleh S; Alhussien A; Alyamani A; Alhussain F; Alhijji A; Binkhamis K; Khan A; Javer A; Alshahrani FS
    BMC Infect Dis; 2024 Mar; 24(1):271. PubMed ID: 38429662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 0.5% povidone-iodine on the nasopharyngeal and oropharyngeal viral loads in patients with COVID-19: A double-blind placebo-controlled randomized clinical trial.
    Sharma P; Singh A; Singh NP; Takhelchangbam N; Kumar R; Yadav R
    J Family Med Prim Care; 2022 Oct; 11(10):6320-6326. PubMed ID: 36618132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.
    Frank S; Capriotti J; Brown SM; Tessema B
    Ear Nose Throat J; 2020 Nov; 99(9):586-593. PubMed ID: 32520599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.
    Anderson DE; Sivalingam V; Kang AEZ; Ananthanarayanan A; Arumugam H; Jenkins TM; Hadjiat Y; Eggers M
    Infect Dis Ther; 2020 Sep; 9(3):669-675. PubMed ID: 32643111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse.
    Bidra AS; Pelletier JS; Westover JB; Frank S; Brown SM; Tessema B
    J Prosthodont; 2020 Jul; 29(6):529-533. PubMed ID: 32511851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.